Jeffrey A. Lieberman, MD

Profile Headshot


Jeffrey A. Lieberman, MD, is the Lawrence C. Kolb Professor of Psychiatry at Columbia University Medical Center. Dr. Lieberman’s work has advanced the understanding of the natural history and pathophysiology of schizophrenia and the pharmacology and clinical effectiveness of antipsychotic drugs.

He is the recipient of many national and international honors and awards, including the Lieber Prize for Schizophrenia Research from the National Association for Research in Schizophrenia and Affective Disorders, the Adolph Meyer Award from the American Psychiatric Association, the Research Award from the National Alliance on Mental Illness, and the Neuroscience Award from the International College of Neuropsychopharmacology.

He is a member of numerous scientific organizations, including the National Academy of Sciences Institute of Medicine. He has authored more than 500 papers and articles published in the scientific literature and written and/or edited ten books on mental illness, psychopharmacology and psychiatry. Dr. Lieberman served as president of the American Psychiatric Association (APA) from May 2013 to May 2014.

Academic Appointments

  • Lieber Professor of Psychiatry
  • Lawrence C. Kolb Professor of Psychiatry

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center


  • Spanish


  • Male

Schedule an Appointment

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In


51 West 51st Street
Suite 340
New York, NY 10019
New Patient Appointments:

Insurance Accepted


  • Behavioral Health (Columbia University Employee Plan)

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • Residency: St Vincents Hospital NY NY
  • Fellowship: Bronx Psychiatric Center

Board Certifications

  • Psychiatry


Dr. Lieberman’s research has been supported by grants from the National Institutes of Health and the NARSAD, Stanley, and Mental Illness Foundations and has focused on the neurobiology, pharmacology and treatment of schizophrenia and related psychotic disorders. In this context, his work has advanced our understanding of the natural history and pathophysiology of schizophrenia and the pharmacology and clinical effectiveness of antipsychotic drugs. In terms of the latter, he served as Principal Investigator of the Clinical Antipsychotic Trials of Intervention Effectiveness Research Program (CATIE), sponsored by the NIMH. He also currently serves as Principal Investigator on the newly awarded NIMH contract Recovery After an Initial Schizophrenic Episode (RAISE) and will lead a multi-institution research team in developing and testing an evidence-based strategic intervention for early psychosis to demonstrate how treatment at the onset of symptoms can prevent the debilitating effects of schizophrenia and related psychotic disorders.

Clinical Trials

Current clinical trials:

  • Cognitive Remediation in Patients with Schizophrenia Stabilized on Lurasidone. Learn more.
  • Evaluating Efficacy and Safety of RO4917838. Learn more.
  • How a New Drug, DAR-0100A, Affects Memory, How You Think, And How You Make Decisions. Learn more.
  • Testing Whether Investigational Drug RO4917838 is Safe and Can Improve Sub-Optimally Controlled Symptoms in Patients With Schizophrenia. Learn more.
  • Studying metabolic changes in non-psychotic adults taking the antipsychotic medications Fanapt (iloperidone) or Zyprexa (olanzapine). Learn more.